GLP-1 Peptides (Semaglutide / Tirzepatide)
The most powerful weight loss tool in modern medicine.
GLP-1 receptor agonists — including Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound) — represent a paradigm shift in metabolic medicine. These physician-prescribed peptides produce levels of sustained weight loss previously only achievable through bariatric surgery, while simultaneously improving nearly every marker of metabolic health.
The Science
How It Works
GLP-1 (glucagon-like peptide-1) is a naturally occurring gut hormone that regulates appetite, insulin secretion, and gastric emptying. GLP-1 agonists mimic and amplify this signal — dramatically reducing hunger, slowing digestion, and improving insulin sensitivity. Tirzepatide adds GIP receptor agonism for an even more powerful dual-action effect.
What to Expect
Key Benefits
Significant, Sustained Weight Loss
Clinical trials show 15–22% body weight reduction with Semaglutide and up to 22.5% with Tirzepatide — results that rival bariatric surgery.
Dramatically Reduced Appetite
Men on GLP-1 protocols consistently report that food noise — the constant preoccupation with eating — essentially disappears.
Improved Insulin Sensitivity
Powerful anti-diabetic effects including improved fasting glucose, HbA1c reduction, and reduced insulin resistance.
Cardiovascular Protection
Semaglutide has demonstrated a 20% reduction in major cardiovascular events in clinical trials — independent of weight loss.
Metabolic Transformation
When combined with hormone optimization, GLP-1 therapy produces comprehensive metabolic improvements that go far beyond weight loss alone.
Find out if GLP-1 Peptides (Semaglutide / Tirzepatide) is right for you.
A free 20-minute call with our physician team. No commitment required.
Who It's For
Men with significant weight to lose, metabolic syndrome, pre-diabetes, or those who have struggled with conventional diet and exercise approaches. Most effective when combined with TRT and lifestyle optimization.
Administration
Weekly subcutaneous injection. Doses are titrated gradually over several weeks to minimize GI side effects. Our protocols include ongoing physician monitoring and dose adjustment.
Safety Profile
Both Semaglutide and Tirzepatide are FDA-approved with extensive clinical trial data. Most common side effects are GI-related (nausea, constipation) and typically resolve as the body adjusts. Contraindicated in personal or family history of medullary thyroid cancer.
Ready to Start a GLP-1 Peptides (Semaglutide / Tirzepatide) Protocol?
Book a free consultation with our medical team. We'll review your labs and determine if GLP-1 Peptides (Semaglutide / Tirzepatide) is right for your goals.